Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Understanding the basis of variability in the response of patients to the dose of a drug and a willingness to vary the dose regimen as well as the choice of drug should be one of the key pillars of precision medicine.
AbbVie's BCL-2 inhibitor venetoclax — the leading small-molecule protein–protein interaction inhibitor — could soon become the first marketed drug to directly target the ability of cancer cells to evade apoptosis.
Ian Tomlinson, former head of business development for GlaxoSmithKline and now chairman of the Apollo Therapeutics Fund, discusses a new model of pharmaceutical–academic partnership.
This article presents a benchmarking analysis that identifies design parameters associated with improved performance in clinical R&D, and hence actions that companies can take to optimize their clinical development operations.
Modulators of glucagon-like peptide 1 (GLP1) and the resulting G protein-coupled receptor (GPCR) signalling have recently come to the fore of the treatment of type 2 diabetes. In this Opinion article, Oh and Olefsky discuss the potential for intervention with other GPCRs for the treatment of this disease, highlighting GPCR-mediated effects on insulin secretion, insulin sensitivity and inflammation.
Members of the integrin family of receptors, which are involved in cell–cell adhesion, have been successfully targeted for cardiovascular disease, multiple sclerosis and inflammatory bowel disease. Ley and colleagues review the biological basis for the development of the next generation of integrin-targeted drugs, highlighting lessons learned from successes and failures.
The gasotransmitters nitric oxide, carbon monoxide and hydrogen sulfide are involved in a large number of physiological processes. In this Review, the author explains how, in cancer, each of these gaseous mediators exhibits a biphasic pharmacological character, whereby increasing or decreasing gasotransmitter concentrations in the tumour can exert antitumour effects.
Single-cell analysis tools are rapidly evolving, enabling cellular analyses at the genomic, transcriptomic and proteomic levels. Here, Heath and colleagues provide an overview of recently developed single-cell analysis technologies, discuss their biological applications and highlight their potential uses in drug discovery and development, focusing on the field of oncology.
